FDA Approves Lilly's Onswik: A New Once-Weekly Insulin for Type 2 Diabetes Management
On September 24, 2026, Eli Lilly and Company celebrated a significant milestone in diabetes management with the FDA’s approval of Onswik (insulin efsitora alfa-gobe), a new once-weekly basal insulin specifically designed for adults living with type 2 diabetes. This innovative treatment aims to simplify insulin administration, reducing the number of injections patients endure each year from 365 to just 52, offering a more manageable approach for diabetes care.
Historically, insulin treatment has involved daily injections, which can be a daunting task for many patients. Dr. Kenneth Custer, executive vice president at Lilly, expressed that Lilly's commitment to transforming diabetes care continues as they seek to provide solutions that enhance patients' everyday experiences. The shoot towards creating Onswik is a direct response to the challenges faced by those managing type 2 diabetes, including the delays in initiating treatment and the stress of multiple daily injections.
Onswik works by providing steady insulin levels throughout the week, enabling adults to maintain stable blood sugar levels while adhering to a diet and exercise regimen. This FDA approval comes after rigorous studies, including the QWINT Phase 3 clinical trials, which evaluated the safety and efficacy of Onswik in over 3,400 adults. These trials aimed to demonstrate non-inferior A1C reductions when compared to traditional daily insulins like insulin glargine U-100 and insulin degludec U-100.
The results have been promising; the safety profile of Onswik was comparable to daily basal insulins, and the data support its efficacy as a treatment option. Common side effects include low blood sugar, allergic reactions, and injection site reactions. Notably, it is important to mention that Onswik is not advisable for individuals with type 1 diabetes due to the heightened risk of severe hypoglycemic events.
Globally, diabetes is a growing concern. As of now, one in eight Americans is living with this chronic condition, with the majority diagnosed with type 2 diabetes. Projections indicate that by 2030, the number of people affected worldwide could exceed 510 million, intensifying the need for effective and versatile treatments. Insulin continues to be a vital option for those whose glycemic goals are not met through other treatments.
With the Onswik KwikPen, patients will have access to two concentrations: 500 units/mL and 1,000 units/mL. This convenient format equips them with a pre-filled pen that can be easily administered in a home setting. The launch of Onswik represents Lilly's fourth global approval for this insulin formulation following earlier nods from regulatory agencies in Europe, Mexico, and Japan.
As a reminder, the transition to a once-weekly insulin should be managed under the guidance of healthcare providers to ensure proper dosing and to mitigate any potential risks associated with dosage errors. Onswik offers a promising future for diabetes management, fostering hope for improved quality of life for millions.
For more in-depth information about Onswik, patients and healthcare providers can visit www.onswik.lilly.com. In conclusion, Lilly’s determination to innovate in the field of diabetes care, as exemplified by Onswik, not only signifies new treatment possibilities but also aligns with their long-standing commitment to improving patient outcomes across the globe.
Historically, insulin treatment has involved daily injections, which can be a daunting task for many patients. Dr. Kenneth Custer, executive vice president at Lilly, expressed that Lilly's commitment to transforming diabetes care continues as they seek to provide solutions that enhance patients' everyday experiences. The shoot towards creating Onswik is a direct response to the challenges faced by those managing type 2 diabetes, including the delays in initiating treatment and the stress of multiple daily injections.
Onswik works by providing steady insulin levels throughout the week, enabling adults to maintain stable blood sugar levels while adhering to a diet and exercise regimen. This FDA approval comes after rigorous studies, including the QWINT Phase 3 clinical trials, which evaluated the safety and efficacy of Onswik in over 3,400 adults. These trials aimed to demonstrate non-inferior A1C reductions when compared to traditional daily insulins like insulin glargine U-100 and insulin degludec U-100.
The results have been promising; the safety profile of Onswik was comparable to daily basal insulins, and the data support its efficacy as a treatment option. Common side effects include low blood sugar, allergic reactions, and injection site reactions. Notably, it is important to mention that Onswik is not advisable for individuals with type 1 diabetes due to the heightened risk of severe hypoglycemic events.
Globally, diabetes is a growing concern. As of now, one in eight Americans is living with this chronic condition, with the majority diagnosed with type 2 diabetes. Projections indicate that by 2030, the number of people affected worldwide could exceed 510 million, intensifying the need for effective and versatile treatments. Insulin continues to be a vital option for those whose glycemic goals are not met through other treatments.
With the Onswik KwikPen, patients will have access to two concentrations: 500 units/mL and 1,000 units/mL. This convenient format equips them with a pre-filled pen that can be easily administered in a home setting. The launch of Onswik represents Lilly's fourth global approval for this insulin formulation following earlier nods from regulatory agencies in Europe, Mexico, and Japan.
As a reminder, the transition to a once-weekly insulin should be managed under the guidance of healthcare providers to ensure proper dosing and to mitigate any potential risks associated with dosage errors. Onswik offers a promising future for diabetes management, fostering hope for improved quality of life for millions.
For more in-depth information about Onswik, patients and healthcare providers can visit www.onswik.lilly.com. In conclusion, Lilly’s determination to innovate in the field of diabetes care, as exemplified by Onswik, not only signifies new treatment possibilities but also aligns with their long-standing commitment to improving patient outcomes across the globe.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.